Literature DB >> 24604205

microRNA-206 overexpression inhibits cellular proliferation and invasion of estrogen receptor α-positive ovarian cancer cells.

Shaoru Li1, Yan Li2, Zhengfang Wen1, Fanjing Kong1, Xinlei Guan1, Wenhui Liu3.   

Abstract

The expression levels of estrogen receptor (ER α) are closely associated with estrogen-dependent growth, invasion and response to endocrine therapy in ERα-positive ovarian cancer. However, the underlying regulatory mechanisms remain to be fully understood. Previous studies have demonstrated that ERα is a direct target of microRNA (miR)-206. miR-206 has been found to be an important tumor suppressor in several cancer types, including ovarian, gastric and laryngeal cancer. However, the specific role of miR-206 in ovarian cancer remains unclear. The aim of the present study was to investigate the role of miR-206 in ER-a positive ovarian cancer in vitro. The present study demonstrated that miR-206 is significantly downregulated in ERα-positive but not ERα‑negative ovarian cancer tissues, compared with normal ovarian epithelium tissue. It was also found that the expression of miR-206 was decreased in ERα-positive ovarian cancer cell lines, CAOV-3 and BG-1, compared with normal ovarian epithelium tissues. This suggests that miR-206 may play a role in ERα-positive ovarian cancer cells via an estrogen-dependent mechanism. Further analysis revealed that 17β-E2 treatment significantly promoted cellular proliferation and invasion of estrogen-dependent CAOV-3 and BG-1 cells, which could be reversed by the introduction of miR-206 mimics. In conclusion, the present study suggests that miR-206 has an inhibitory role in estrogen-dependent ovarian cancer cells. Thus, miR-206 may be a promising candidate for the endocrine therapy of ERα-positive ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24604205     DOI: 10.3892/mmr.2014.2021

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  17 in total

1.  Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma.

Authors:  Rong Tian; Tao Liu; Li Qiao; Mei Gao; Jing Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  [Role of miR-206/CDK4 in modulating the growth and chemotlerapy sensitivity of ovarian cancer cells].

Authors:  Chen Ling; Shu Liu; Yong Wang; Feng-Chun Zhang; Ying DU
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-03-20

Review 3.  MicroRNAs in gynecological cancers: Small molecules with big implications.

Authors:  Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh
Journal:  Cancer Lett       Date:  2017-05-24       Impact factor: 8.679

4.  Expression Profiles of Estrogen-Regulated MicroRNAs in Cancer Cells.

Authors:  Amena Archer; Claudia Kutter; Cecilia Williams
Journal:  Methods Mol Biol       Date:  2022

5.  Regulation of the T-box transcription factor Tbx3 by the tumour suppressor microRNA-206 in breast cancer.

Authors:  Sumaira Amir; Catalina Simion; Maxine Umeh-Garcia; Sheryl Krig; Tyler Moss; Kermit L Carraway; Colleen Sweeney
Journal:  Br J Cancer       Date:  2016-04-21       Impact factor: 7.640

6.  Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer.

Authors:  Hanyu Ma; Tian Tian; Shuang Liang; Xubin Liu; Hongwei Shen; Meng Xia; Xingyang Liu; Wenhui Zhang; Liantang Wang; Shangwu Chen; Li Yu
Journal:  Oncotarget       Date:  2016-03-01

Review 7.  The role of microRNAs expression in laryngeal cancer.

Authors:  Xin Yu; Zheng Li
Journal:  Oncotarget       Date:  2015-09-15

8.  Smad3-related miRNAs regulated oncogenic TRIB2 promoter activity to effectively suppress lung adenocarcinoma growth.

Authors:  Yan-Xia Zhang; Yun-Fei Yan; Yue-Mei Liu; You-Jie Li; Han-Han Zhang; Min Pang; Jin-Xia Hu; Wei Zhao; Ning Xie; Ling Zhou; Ping-Yu Wang; Shu-Yang Xie
Journal:  Cell Death Dis       Date:  2016-12-22       Impact factor: 8.469

9.  Apigenin Inhibits Histamine-Induced Cervical Cancer Tumor Growth by Regulating Estrogen Receptor Expression.

Authors:  Erkang Zhang; Yani Zhang; Zhuoyan Fan; Lei Cheng; Shiwen Han; Huilian Che
Journal:  Molecules       Date:  2020-04-23       Impact factor: 4.411

10.  MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2.

Authors:  Shujun Feng; Wenjing Pan; Ye Jin; Jianhua Zheng
Journal:  Tumour Biol       Date:  2014-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.